JP2020520677A - 高アンモニア血症を治療するためのグルタミン合成酵素の使用 - Google Patents

高アンモニア血症を治療するためのグルタミン合成酵素の使用 Download PDF

Info

Publication number
JP2020520677A
JP2020520677A JP2020515296A JP2020515296A JP2020520677A JP 2020520677 A JP2020520677 A JP 2020520677A JP 2020515296 A JP2020515296 A JP 2020515296A JP 2020515296 A JP2020515296 A JP 2020515296A JP 2020520677 A JP2020520677 A JP 2020520677A
Authority
JP
Japan
Prior art keywords
protein
ammonia
hyperammonemia
composition
lowering agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020515296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520677A5 (enExample
Inventor
タマラ・ニコルソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thoeris GmbH
Original Assignee
Thoeris GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1708288.4A external-priority patent/GB201708288D0/en
Priority claimed from GBGB1800867.2A external-priority patent/GB201800867D0/en
Application filed by Thoeris GmbH filed Critical Thoeris GmbH
Publication of JP2020520677A publication Critical patent/JP2020520677A/ja
Publication of JP2020520677A5 publication Critical patent/JP2020520677A5/ja
Priority to JP2023038030A priority Critical patent/JP7688926B2/ja
Priority to JP2024026784A priority patent/JP2024059833A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020515296A 2017-05-24 2018-05-24 高アンモニア血症を治療するためのグルタミン合成酵素の使用 Pending JP2020520677A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023038030A JP7688926B2 (ja) 2017-05-24 2023-03-10 高アンモニア血症を治療するためのグルタミン合成酵素の使用
JP2024026784A JP2024059833A (ja) 2017-05-24 2024-02-26 高アンモニア血症を治療するためのグルタミン合成酵素の使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1708288.4 2017-05-24
GBGB1708288.4A GB201708288D0 (en) 2017-05-24 2017-05-24 Use of glutamine synthetase for treating hyperammonemia
GB1800867.2 2018-01-19
GBGB1800867.2A GB201800867D0 (en) 2018-01-19 2018-01-19 Use of glutamine synthetase for treating hyperammonemia
PCT/GB2018/051415 WO2018215780A1 (en) 2017-05-24 2018-05-24 Use of glutamine synthetase for treating hyperammonemia

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023038030A Division JP7688926B2 (ja) 2017-05-24 2023-03-10 高アンモニア血症を治療するためのグルタミン合成酵素の使用
JP2024026784A Division JP2024059833A (ja) 2017-05-24 2024-02-26 高アンモニア血症を治療するためのグルタミン合成酵素の使用

Publications (2)

Publication Number Publication Date
JP2020520677A true JP2020520677A (ja) 2020-07-16
JP2020520677A5 JP2020520677A5 (enExample) 2021-07-26

Family

ID=62492675

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020515296A Pending JP2020520677A (ja) 2017-05-24 2018-05-24 高アンモニア血症を治療するためのグルタミン合成酵素の使用
JP2023038030A Active JP7688926B2 (ja) 2017-05-24 2023-03-10 高アンモニア血症を治療するためのグルタミン合成酵素の使用
JP2024026784A Pending JP2024059833A (ja) 2017-05-24 2024-02-26 高アンモニア血症を治療するためのグルタミン合成酵素の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023038030A Active JP7688926B2 (ja) 2017-05-24 2023-03-10 高アンモニア血症を治療するためのグルタミン合成酵素の使用
JP2024026784A Pending JP2024059833A (ja) 2017-05-24 2024-02-26 高アンモニア血症を治療するためのグルタミン合成酵素の使用

Country Status (11)

Country Link
US (4) US12359184B2 (enExample)
EP (3) EP4295904A3 (enExample)
JP (3) JP2020520677A (enExample)
KR (2) KR20250093434A (enExample)
CN (2) CN118105471A (enExample)
AU (2) AU2018272294B2 (enExample)
BR (1) BR112019024750A2 (enExample)
CA (1) CA3064352A1 (enExample)
IL (1) IL270817B2 (enExample)
MX (2) MX2019014027A (enExample)
WO (1) WO2018215780A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023085301A (ja) * 2017-05-24 2023-06-20 テリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高アンモニア血症を治療するためのグルタミン合成酵素の使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856231A1 (en) * 2018-09-28 2021-08-04 Thoeris GmbH Use of glutamine synthetase for treating fatty liver disease
CN110133287B (zh) * 2019-05-22 2021-07-30 上海碧云天生物技术有限公司 蛋白抽提溶液及其应用
JP2023532939A (ja) 2020-06-30 2023-08-01 インダストリー－アカデミック コーオペレイション ファウンデーション キョンサン ナショナル ユニバーシティ チロシンを有効成分として含むタンパク質内のチロシンのニトロ化による疾患の予防、改善または治療用組成物
JP2024168541A (ja) 2023-05-24 2024-12-05 トヨタ自動車株式会社 二次電池
CN118949035A (zh) * 2024-07-31 2024-11-15 北京大学第一医院(北京大学第一临床医学院) Glul生物标志物在心力衰竭诊断、治疗或预后预测中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527754A (ja) * 2001-04-25 2004-09-09 シンエックス・ファルマ・インコーポレーテッド アルツハイマー型痴呆の鑑別診断処理及びその装置
JP2007525997A (ja) * 2004-03-02 2007-09-13 アドネクサス セラピューティクス インコーポレーティッド アドザイムおよびその使用法
JP2013529911A (ja) * 2010-05-28 2013-07-25 マインド−エヌアールジー ソシエテ アノニム ニューレグリンアイソフォーム、ニューレグリンポリペプチドおよびその使用法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AUPR805101A0 (en) 2001-10-03 2001-10-25 University Of New South Wales, The A method of genetic screening using an amplifiable gene
JP2003225093A (ja) 2001-11-30 2003-08-12 Sumitomo Pharmaceut Co Ltd 軟骨障害マーカー及びその利用
US6875792B2 (en) 2002-01-31 2005-04-05 Mso Pharma Llc Dosage form of L-Methionine S-Sulfoximine
JP2003274963A (ja) 2002-03-22 2003-09-30 Japan Science & Technology Corp 遺伝子組換え細胞株及びそれを用いた肝機能補助装置
EP1578996A4 (en) 2002-10-18 2007-12-19 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
CA2503390A1 (en) 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
WO2004106489A2 (en) 2003-05-21 2004-12-09 Divergence, Inc Nematode GS-like sequences
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20070098702A1 (en) * 2005-02-17 2007-05-03 University Of Maryland, Baltimore Recombinant protein polymer vectors for systemic gene delivery
EP1752143A1 (en) 2005-08-08 2007-02-14 NewThera Novel uses for drugs targeting glutamine synthetase
WO2007071339A1 (en) 2005-12-21 2007-06-28 Universite Catholique De Louvain Isolated liver stem cells
RU2362572C2 (ru) 2007-07-17 2009-07-27 Юрий Георгиевич Каминский Способ снижения концентрации аммиака в крови с помощью аммоцитов и инкапсулированной глутаминсинтетазы
PL3133396T3 (pl) * 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Sposób leczenia z zastosowaniem leków wychwytujących amoniak
JP2012501641A (ja) 2008-09-08 2012-01-26 セレクティス グルタミンシンセターゼ遺伝子からのｄｎａ標的配列を切断するメガヌクレアーゼ変異型及びその使用
WO2013020914A1 (en) * 2011-08-10 2013-02-14 Celares Gmbh Peg-conjugated peptides
WO2013137583A1 (en) 2012-03-12 2013-09-19 Hanwha Chemical Corporation An expression vector comprising a polynucleotide encoding a modified glutamine synthetase and a method for preparing a target protein employing the same
EP2674495A1 (en) 2012-06-14 2013-12-18 Sanofi CHO expression system
MX377806B (es) 2014-11-07 2025-03-11 Instituto Nac De Ciencias Medicas Y Nutricion Salvador Zubiran Uso de un baculovirus recombinante que media la expresión de la glutamina sintetasa para tratar la encefalopatía hepática.
NZ732632A (en) * 2014-11-24 2021-07-30 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
EP3307879A2 (en) * 2015-06-10 2018-04-18 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
KR102479894B1 (ko) 2016-03-30 2022-12-21 스파크 테라퓨틱스, 인코포레이티드 재조합 단백질 및/또는 바이러스 벡터 생산용 세포주
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
TWI821905B (zh) 2016-05-11 2023-11-11 美商安美基公司 使用麩醯胺合成酶基因內互補載體直接選擇表現高水準異質蛋白的細胞
CN110023500B (zh) 2016-11-16 2024-10-11 新加坡科技研究局 作为选择标记的减毒谷氨酰胺合成酶
EP4295904A3 (en) 2017-05-24 2024-02-28 Thoeris GmbH Use of glutamine synthetase for treating hyperammonemia
US11479792B2 (en) 2017-07-13 2022-10-25 Upside Foods, Inc. Compositions and methods for increasing the efficiency of cell cultures used for food production
US11713468B2 (en) 2017-08-02 2023-08-01 Dna Twopointo Inc. DNA vectors and elements for sustained gene expression in eukaryotic cells
CN109988777A (zh) 2017-12-29 2019-07-09 南京金斯瑞生物科技有限公司 谷氨酰胺合成酶基因以及应用
CN110714057A (zh) 2018-07-11 2020-01-21 成都金洛克生物技术有限公司 用于检测外源基因整合和定位的通用型fish探针及其应用
CN109504709B (zh) 2018-11-28 2020-07-24 上海安民生物技术有限公司 白蛋白启动子驱动的白蛋白表达载体
AU2020225647B2 (en) 2019-02-22 2025-06-05 Smith & Nephew Asia Pacific Pte Limited Combination electrosurgical and mechanical resection device
WO2020227206A1 (en) 2019-05-07 2020-11-12 Amgen Inc. Vectors and expression systems for producing recombinant proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527754A (ja) * 2001-04-25 2004-09-09 シンエックス・ファルマ・インコーポレーテッド アルツハイマー型痴呆の鑑別診断処理及びその装置
JP2007525997A (ja) * 2004-03-02 2007-09-13 アドネクサス セラピューティクス インコーポレーティッド アドザイムおよびその使用法
JP2013529911A (ja) * 2010-05-28 2013-07-25 マインド−エヌアールジー ソシエテ アノニム ニューレグリンアイソフォーム、ニューレグリンポリペプチドおよびその使用法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"VANCOUVER GENERAL HOSPITAL CSU PHARMACEUTICAL SCIENCES SPECIAL ACCESS PROGRAM (SAP) DRUG DATA SHEET,", [ONLINE], JPN5020007046, July 2007 (2007-07-01), pages 1, ISSN: 0005130136 *
GENE THERAPY, vol. VOL:22, NR:1,, JPN5020007045, 23 October 2014 (2014-10-23), GB, pages 58 - 64, ISSN: 0005130134 *
池田豊: "医薬品開発のためのPEG材料設計", DRUG DELIVERY SYSTEM, vol. 31(4), JPN6022010323, 2016, pages 268 - 274, ISSN: 0005130135 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023085301A (ja) * 2017-05-24 2023-06-20 テリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高アンモニア血症を治療するためのグルタミン合成酵素の使用
JP7688926B2 (ja) 2017-05-24 2025-06-05 テリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高アンモニア血症を治療するためのグルタミン合成酵素の使用

Also Published As

Publication number Publication date
MX2019014027A (es) 2020-08-03
BR112019024750A2 (pt) 2020-06-09
US11932885B2 (en) 2024-03-19
CN118105471A (zh) 2024-05-31
KR20200018488A (ko) 2020-02-19
WO2018215780A1 (en) 2018-11-29
IL270817B2 (en) 2025-10-01
US20240150746A1 (en) 2024-05-09
AU2018272294B2 (en) 2024-05-23
JP7688926B2 (ja) 2025-06-05
EP3630077A1 (en) 2020-04-08
JP2023085301A (ja) 2023-06-20
AU2024201089A1 (en) 2024-03-14
US20210145946A1 (en) 2021-05-20
EP4295904A3 (en) 2024-02-28
AU2018272294A1 (en) 2020-01-16
CA3064352A1 (en) 2018-11-29
MX2024002249A (es) 2024-03-05
IL270817B1 (en) 2025-06-01
US20220401532A1 (en) 2022-12-22
IL270817A (en) 2020-01-30
JP2024059833A (ja) 2024-05-01
CN111093641A (zh) 2020-05-01
KR20250093434A (ko) 2025-06-24
AU2024201089B2 (en) 2025-04-24
EP4295904A2 (en) 2023-12-27
EP4119133A1 (en) 2023-01-18
US12338471B2 (en) 2025-06-24
US20220401531A1 (en) 2022-12-22
US12359184B2 (en) 2025-07-15

Similar Documents

Publication Publication Date Title
JP7688926B2 (ja) 高アンモニア血症を治療するためのグルタミン合成酵素の使用
US20240035013A1 (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
HK40087273A (en) Glutamine synthetase protein conjugate
EA050582B1 (ru) Применение глутамин-синтетазы для лечения гипераммониемии
US12414986B2 (en) Use of glutamine synthetase for treating fatty liver disease
WO2022073134A1 (en) Annexin a5 compositions and methods
EP4341394A1 (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
HK40081555A (en) Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210521

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240315

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240531

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250217